Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Complement C5
  • Hemolytic-Uremic Syndrome
  • Thrombotic Microangiopathies

abstract

  • Eculizumab inhibited complement-mediated thrombotic microangiopathy and was associated with significant time-dependent improvement in renal function in patients with atypical hemolytic-uremic syndrome. (Funded by Alexion Pharmaceuticals; C08-002 ClinicalTrials.gov numbers, NCT00844545 [adults] and NCT00844844 [adolescents]; C08-003 ClinicalTrials.gov numbers, NCT00838513 [adults] and NCT00844428 [adolescents]).

publication date

  • June 10, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1208981

PubMed ID

  • 23738544

Additional Document Info

start page

  • 2169

end page

  • 81

volume

  • 368

number

  • 23